High-dose intravenous vitamin C dosed by how the body clears it for people with advanced solid tumors
Official title: Phase I Clinical Study of a New High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics in Combination With Standard Systemic Therapy for Patients With Advanced Malignant Solid Tumors
Run by Zhongnan Hospital · NCT07121036 · Data updated 2026-11-12
This trial tests whether giving high-dose IV vitamin C based on each patient's pharmacokinetics can be delivered safely and produce anti-tumor effects in adults with advanced or metastatic solid tumors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Zhongnan Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | March 30, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | August 13, 2025 |
| Trial ID | NCT07121036 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with histologically or cytologically confirmed advanced or metastatic malignant solid tumors, ECOG performance status 0–1, at least one measurable lesion, adequate bone marrow/liver/kidney/heart function, no history of calcium oxalate kidney stones, and catalase-negative pathology are the intended participants.
✕Probably not a fit
Patients with poor performance status (ECOG >1), significant organ dysfunction, a history of calcium oxalate kidney stones, or tumors positive for catalase by immunohistochemistry are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, single-center interventional trial testing a high-dose intravenous vitamin C regimen tailored to patients' pharmacokinetic characteristics. The primary focus is on safety, tolerability, and pharmacokinetics, with collection of preliminary anti-tumor activity data in adults with advanced or metastatic solid tumors. Eligible participants must have ECOG 0-1, at least one measurable lesion, adequate organ function, no history of calcium oxalate kidney stones, and tumor tissue negative for catalase by immunohistochemistry. Treatments and follow-up visits are conducted at Zhongnan Hospital of Wuhan University.
Why it matters
Potential benefit: If successful, the approach could enable safe achievement of therapeutic plasma vitamin C levels that might slow tumor growth or improve symptoms for some patients.
How similar studies have gone: Previous investigations have produced mixed results—early case reports suggested benefit, a Mayo Clinic randomized trial did not show efficacy, and later work indicates IV high-dose vitamin C reaches much higher plasma levels with phase 1 studies showing relative safety but no consistent proof of clinical benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged 18 - 75 years old, regardless of gender. 2. The subject voluntarily participates, gives full informed consent, signs a written informed consent form, and has good compliance. 3\. Histologically or cytologically pathologically diagnosed as advanced or metastatic malignant solid tumor. 4\. Physical function status: Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1. 5\. The patient must have at least one measurable lesion (RECIST 1.1). 6. Sufficient bone marrow, liver, kidney, and heart function were recorded within 7 days before enrollment, and the patient is suitable for routine chemotherapy indicated clinically according to normal care standards. 7\. No history of calcium oxalate kidney stones. 8. Expected survival ≥ 12 weeks. 9. Pathological immunohistochemistry requires a negative catalase result. 10. Patients who are undergoing systemic anti - tumor treatment and have disease progression can also enter the protocol, continue the same treatment or start a different chemotherapy regimen without interruption. Exclusion Criteria: * 1\. Lack of pathological diagnosis of malignant solid tumor. 2. The patient currently has central nervous system (CNS) metastasis or a history of brain metastasis. 3\. Severe gastrointestinal diseases, including active bleeding. 4. Patients with severe or uncontrolled infections, heart or nervous system diseases. 5\. Major surgery within 4 weeks or local radiotherapy within 7 days before the administration of the study drug. 6\. Dementia or severe mental status changes that prevent obtaining informed consent. 7\. Women of childbearing potential must use an acceptable contraceptive method during the study and must undergo a pregnancy test within 7 days after the first chemotherapy. 8\. The patient currently has poorly controlled diabetes (fasting blood glucose (FBG) \> 10 mmol/L). 9\. Glucose - 6 - phosphate dehydrogenase (G6PD) deficiency or hereditary spherocytosis. 10\. Active pulmonary tuberculosis (TB), patients who are undergoing anti - tuberculosis treatment or have received anti - tuberculosis treatment within 1 year before the first drug administration; patients with positive human immunodeficiency virus (HIV) antibodies; or patients with syphilis infection. 11\. Active viral hepatitis. If HBsAg (+) and/or HBcAb (+), HBV DNA must be \< 500 IU/mL, and during the study, the patient must continue the original anti - HBV treatment throughout the process or start using entecavir or tenofovir throughout the process. Patients with positive hepatitis C virus (HCV) ribonucleic acid (RNA) must receive antiviral treatment according to local standard treatment guidelines and have liver function within Grade 1 elevation of NCI - CTCAE Version 5.0. 12\. Any abnormal laboratory values or medical conditions that, in the judgment of the investigator, make the patient unfit for the study.
Where it's running
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Lei Yang, Dr
- Email: leiyangwhu@whu.edu.cn
- Phone: +86-027-67812592
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gingival Depigmentation with Vitamin C and Glutathione vs. Surgical Depigmentation
This study tests whether vitamin C with glutathione injections can depigment pigmented gums as effectively as surgical depigmentation in adults.
-
Vitamin C to shorten hospital stay for children with severe pneumonia
This trial will test whether giving vitamin C along with usual treatment helps children under five with severe pneumonia get better faster and leave the hospital sooner.
-
Vitamin D Supplementation in Children with Irritable Bowel Syndrome
This study tests whether giving vitamin D to children with IBS and low vitamin D levels can improve their IBS symptoms compared with a placebo.
-
Vitamin D and dental implant osseointegration in adults with deficiency
This study tests whether giving vitamin D helps improve how well dental implants fuse with bone in adults who are deficient.
-
Vitamin D2 with Calcitriol in kids with cholestasis and vitamin D deficiency
This study tests whether adding calcitriol to vitamin D2 helps children with cholestasis and vitamin D deficiency reach healthier vitamin D levels.
-
Vitamin D and the body's anti-inflammatory response in gum disease
This study tests whether vitamin D can modulate the body's anti-inflammatory response in people with gum disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.